CSO & Co-founder
Business Developer Manager
Business Developer Manager
Intern Business Developer
Have you studied computer science, computer engineering, biofinformatics, computational chemistry or medicinal chemistry?
Are you willing to work in an innovative software company?
Do you enjoy team working, innovation and challenging the status quo?
Are you looking for an industrial PhD degree on computer science or computational chemistry?
Send us your CV and a couple of references to hr[@]pharmacelera.com and join us!
Enric holds a PhD in Computer Engineering from Universitat Politècnica de Catalunya (UPC) and an Executive General Management Program degree from IESE Business School. Enric was a research visitor at the University of Illinois at Urbana Champaign and he worked for 10 years at Intel, where he led international teams from Israel, Germany, the United States and Spain in the fields of High-Performance Computing and Hardware/Software co-design. Enric is a co-author in 25 scientific publications and 20 filed patents and he was co-director of 3 PhD theses. Enric is co-founder and CEO of Pharmacelera.
Javier is a full-time professor at the University of Barcelona (UB), where he leads the Computational Biology and Drug Design (CBDD) research group, and he has a broad expertise in computational chemistry, medicinal chemistry and Computer-Aided Drug Design software. Javier has authored more than 400 publications that have been referenced more than 15,000 times, has an h-index of 72 based on Google Scholar and accumulates 12% of the official references of MOPAC (the open-source QM package).
Enric holds a PhD in Computer Engineering from Universitat Politècnica de Catalunya (UPC), where he obtained the UPC Award for Outstanding PhD Thesis. Enric was a research visitor at the University of California at San Diego. He is a co-founder of Pharmacelera and leads the Research & Development efforts. Prior to that, he worked at Intel in machine learning and hardware acceleration. Enric is a co-author in 14 scientific publications and 17 patents and has been co-director of 1 PhD thesis.
Greta holds a Business degree form Univeristat de Barcelona and Financial Management and Controlling postgraduate courses from UPF Barcelona School of Management. Greta accumulates more than 10 years of experience in finance management positions, focusing the last 6 years in Biotech and SaaS companies.
Rémy has over 30 years of experience in Sales and Business Development across various industries. He has experience in positioning and selling Computational Chemistry Medicinal Chemistry, ADME, Tox, Biology, Scale-up chemistry products and services. His areas of expertise include Providing effective sales techniques for Products & Services; Developing sales strategies; Nurturing and developing collaborative projects; Scientific Support to sales organisations; Transversal interaction with Product Marketing and R&D teams; Interaction with various customers (researchers from the pharma, biotech, academic and government teams) and Team Management.
He has published several articles in Computational Chemistry, and has co-edited two books (pharmacophores, data mining).
Prior to joining Pharmacelera, Rémy was associated with Jubilant Biosys as Senior Director Business Development for Discovery Services in Europe. Prior to Jubilant Biosys, he was associated with companies like Sai Life Sciences, BioAscent Discovery Ltd, Prestwick Chemicals, Thomson Reuters, Accelrys, etc.
He holds a Pharmacy degree and a Ph.D (Medicinal Chemistry) from Louis Pasteur University, Strasbourg, France.
Fernando holds a PhD degree in Computational Chemistry from Universidad Autónoma de Madrid (UAM) and he did a post-doc in the NMR unit of the San Raffaele Hospital in Milan applying molecular modelling techniques to epigenetic diseases. Fernando accumulates 5 years of experience in business development and product management in technology companies in the area of drug discovery. Fernando is co-author in 7 publications.
Ana holds a Pharmacy degree, a specialization in Molecular Biology, and a PhD in Computational Toxicology from Jozef Stefan International Postgraduate School, Ljubljana, Slovenia. She accumulates 6 years of experience in the development and application of computational methods for toxicity evaluation. Ana has published 6 scientific articles in Computational Chemistry and Drug Discovery. Ana has experience working in business development within the drug discovery ecosystem.
Anna is currently studying a double degree in Pharmacy and Nutrition at the University of Barcelona. At Pharmacelera Anna joined the business and development team to work with them and gain experience in this field. She is really interested in chemistry.
Tiziana obtained her PhD in Food Science and Technology with mention of excellence at the University of Parma (Italy) with a thesis focused on the application of computational techniques to food-related topics. During this period, she also contributed to the early development of QM-derived descriptors implemented in the PharmQSAR software. She accumulated 8 years of experience in computational chemistry and drug discovery working in academia. She was postdoctoral researcher in the Computational Biology and Drug Design research group at the University of Barcelona (Spain) and at the Spanish National Research Council (CIB-CSIC) in Madrid (Spain). She was also invited researcher at the University of Bristol (UK). She co-authored more than 25 peer-reviewed papers.
Javier holds a PhD in Computational Chemistry from Universitat de Barcelona (UB). His thesis was co-directed by Professor Javier Luque and Enric Herrero. Javier accumulates 6 years of experience in computational chemistry and molecular modelling and he has been an active contributor to the development of PharmScreen and PharmQSAR since he joined the company. Javier is co-author in 3 chemistry publications and 1 patent.
Albert holds a Computer Science degree from Universitat Politècnica de Catalunya (UPC), a MSc in Software Engineering from Universitat Oberta de Catalunya (UOC) and a MSc in Computational Engineering and Mathematics from Universitat Rovira i Virgili (URV). Albert accumulates more than 10 years of experience in software development and High-Performance Computing. Albert is co-author in 1 publication.
Minyi holds a PhD in Chemical Biology from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (SIOC) and she did a post-doc at the University of Barcelona (UB). Minyi accumulates 5 years of experience in the theoretical study and practical application of structure-based drug design. Minyi is co-author in 8 publications.
Ruqaiya obtained her PhD in molecular medicine from University of Karachi (Pakistan) with a dissertation focused on the application of computational chemistry techniques on different biological targets. She was also a guest researcher at the University of Copenhagen (Denmark). Prior to joining Pharmacelera, she was postdoctoral researcher in the Computational Molecular Evolution group at the University of Vigo (Spain). She co-authored more than 30 peer-reviewed papers. She accumulated 7 years of experience in computational chemistry and drug discovery working in academia.
Marc holds a Higher-Level Training Cycle in telecommunications and is finishing a degree of Telematic Engineering from La Salle University. He brings more than six years of experience in Front-End and Back-End development in big Banking applications and e-commerce applications, those companies are among the most important Spanish companies.
Brian holds a Chemistry Degree from Universitat Autònoma de Barcelona and a MSc in Bioinformatics from Universitat Pompeu Fabra. He accumulates more than 2 years of experience in molecular simulations and computational chemistry. At Pharmacelera, Brian is developing his PhD in Computational Chemistry under the direction of Dr. Javier Vázquez and Prof. Jana Selent (IMIM). Brian is co-author in 5 scientific publications.
Miquel is part of the first promotion of the Pharmacy degree program with a focus on drug design and production, at IQS-Blanquerna. He is currently pursuing his PhD in Chemistry and Chemical Engineering, specializing in organic and pharmaceutical chemistry, at IQS. His research is primarily focused on the design of lymphoma treatments using molecular modelling techniques. Miquel has also gained practical experience in his field through a research assistantship, where he contributed to projects in organic chemistry and pharmaceutical technology.
Carol holds a Ph.D. in Chemical Science and Technology from University of Balearic Islands (UIB), awarded as Outstanding PhD Thesis. During her PhD, she was a research visitor at University of Barcelona, Catalan Institute of Chemical Research (Tarragona) and Sheffield University. Carol performed several post-doctoral stays at Masaryk University (Czech Republic), University of Barcelona (UB) and University College London (UCL), in the latest as a Marie Curie Fellow. Now, she is a lecturer professor at the University of Barcelona (UB), joining the Computational Biology and Drug Design (CBDD) research group. She has experience in computational chemistry and drug discovery, with a high expertise in the use of a wide variety of computational techniques. Carol has authored more than 50 peer-reviewed publications that have been referenced more than 2,000 times, and has an h-index of 24 based on Google Scholar.
Alex is a last-year student of Computer Science degree from the Universitat Politècnica de Catalunya (UPC). At Pharmacelera, Alex is developing his bachelor’s thesis and working in the backend.
Albert is a bachelor student of Bioinformatics at the School of International Business of the Universitat Pompeu Fabra (ESCI-UPF), a joint degree offered by UPF, UPC, UB and UAB. At Pharmacelera, he is developing his thesis on virtual screening with dynamic libraries.
Woody Sherman holds a Ph.D. in computational chemistry from the Massachusetts Institute of Technology. During graduate school he founded MolySym, an educational technology company focused on designing human-computer interfaces to improve physical science learning. He also worked at Biogen where he applied novel computational methods for antibody affinity optimization, culminating in a patent and publications. He joined Schrödinger in 2004 where he spent more than 12 years developing and applying advanced computational methods used at biotechnology and pharmaceutical companies throughout the world. As vice president and global head of applications sciences at Schrodinger, Woody led many of the breakthrough projects, including Induced Fit Docking, WaterMap, High-Throughput Virtual Screening, Protein Preparation Wizard, and FEP+. Woody is a key opinion leader in molecular simulations, computer-aided drug design and high-performance computing. He has co-authored more than 80 publications in several fields of computational chemistry and drug discovery. Woody is currently the chief scientific officer at Silicon Therapeutics and an adjunct professor in biochemistry and molecular biology at the University of Massachusetts Amherst.
Mariana holds a PhD in Chemistry from Universidad de Santiago de Chile and she later performed post-doc stays at the University of Durham and Universität Konstanz working on Quantum Mechanics. Mariana is an experienced multilingual and multicultural entrepreneur and manager in the software and scientific industries. She accumulates 25 years of experience in Marketing and Business Development in the Life and Materials Science sector in companies such as Accelrys (now DS Biovia), Perkin Elmer, Dotmatics and Collaborative Drug Discovery (CDD). She also serves as advisor and member of the board in several life science companies.
Manel holds a PhD in Medicinal Chemistry and Molecular Modelling from Universitat de Barcelona (UB) and a Master Degree in Organic Chemistry from the same university. Manel accumulates more than 25 years of industrial experience in the fields of molecular modelling, medicinal and organic chemistry and drug discovery. He worked for 22 years in Almirall and he is now the head of Computational Chemistry at AB Science. Manel is co-author in one patent and in 26 scientific publications.
Albert holds a Pharmacy degree from Universitat de Barcelona (UB), an MBA from EADA Business School and a Stanford School of Business and ESADE Business School degree on Corporate Social Responsibility. Albert accumulates 18 years of experience in business development, technology transfer, marketing and entrepreneurship in the areas of biotechnology, medical devices, digital health and drug discovery in Barcelona and Silicon Valley. He has raised more than 10M euros in his different roles and has served as mentor and board member in more than 10 start-ups.
Joan holds a degree in Medicine from Universitat Autònoma de Barcelona (UAB), a Management Degree from IESE Business School, a Business and Finance degree from Harvard Business School and a master’s degree in Biomedicine, Biotechnology and EU Law from UNED. He currently is the Director of Innovation at Hospital Clínic and the Director of Strategy and Innovation at Barcelona Institute for Global Health (ISGlobal). Joan is an internationally recognized person in the healthcare and pharmaceutical sector, working for 10 years as Medical Director at Bayer and 11 years as Director at Novartis.
Albert has over 30 years expertise in the drug discovery and chemical development of anti-infectives and CNS and pain/inflammation modulators. He holds a PhD in chemistry for the Max Planck in Germany. Before founding the start-up Abac Therapeutics where he participated in the raise of 16m€ in a series-A round, he served at Ferrer, Ciba-Geigy and Menarini, where he was co-discoverer of the marketed analgesic Enantyum©. At Ferrer he was co-discoverer of the topic quinolone antibiotic Ozanex© /Xepi©, and the CNS drug Lorediplon© in clinical development for the treatment of transient insomnia. He is the author of over 55 peer reviewed articles and of 35 issued patents and serves as scientific advisor and member of the board in 2 start-ups.
Venkat Reddy, PhD, is the CSO of General Inception as well as serving on the Board of both Tactile Therapeutics which he co-founded and Pharmacelera.
Prior to joining General Inception in February 2022, Venkat was the CEO/CSO at Macrophage Pharma Ltd, and was responsible for R&D strategy, operations and fundraising activities.
Venkat has a successful track record and extensive strategic and management experience from senior executive roles in both European and US biotech and pharma, including Glenmark Pharmaceuticals (SVP, Global Head of Translational Sciences) managing translational strategy for Glenmark’s innovative medicines portfolio, Pfizer (Senior Director, Strategic Alliances and Partnerships, Centers for Therapeutic Innovation), Sanofi (Senior Director, Head, Bio-Innovation France: Global Biotherapeutics) and Novartis (Group leader, GNF).
Venkat holds a PhD from the Ludwig-Maximilians Universität München, undertook post-doctoral studies in immunology and oncology at the Scripps Research Institute and a Masters in Biotechnology at Jawaharlal Nehru University.
Yamina, Founder & CEO of GlobalReach BI, is a highly accomplished professional in the Life Sciences industry with over 30 years of experience in International Business Development and Information Technology. Yamina holds a Business Degree from Université Blaise Pascal in Clermont-Ferrand, France.
Yamina’s journey in the Life Sciences industry began at Thomson Reuters where she partnered with global pharmaceutical companies in facilitating their development strategies. This experience laid the foundation for her to establish her own Strategic Intelligence Firm, GlobalReach BI, ten years ago. The firm’s mission is to support the development and market launch of new patient treatments.
Based in San Francisco, GlobalReach BI has always been at the forefront of innovation in the Life Sciences industry. GlobalReach BI’s use of AI technology has enabled it to provide its client partners with a wealth of data-driven insights. These insights have facilitated faster and more accurate decision-making processes in the development and market launch of new patient treatments. This innovation has put GlobalReach BI at the forefront of the Life Sciences industry.
Looking forward, Yamina is excited to see what the future holds for GlobalReach BI and the Life Sciences industry as a whole. With the rapid advancements in AI technology, there are endless possibilities for innovation and discovery. Yamina and her team at GlobalReach BI are committed to pushing the boundaries of innovation and staying ahead of the curve in the Life Sciences industry.